The treatment of the SVF from lipedema patients with IPI-549, a selective phosphatidylinositol-3 kinase γ inhibitor that switches M2 macrophages towards an M1-like phenotype, caused an almost complete downregulation of macrophage CD163. The gene discussed is CD163; the disease is Lipedema.